Pfizer new drug could provide a new treatment option for postmenopausal women
Pfizer new drug BZA/CE could provide a new treatment option for symptomatic postmenopausal women with a uterus – Pfizer Inc. will announce new one-year results from the Selective estrogens, Menopause, And Response to Therapy [SMART]-5 Phase 3 study of the safety and efficacy of the investigational tissue selective estrogen complex (TSEC) bazedoxifene/conjugated estrogens (BZA/CE) at the 22nd annual meeting of the North American Menopause Society (NAMS), September_21-24 in Washington, D.C.